Abstract
Cognitive impairment can be demonstrated in Parkinson’s disease (PD) from the very beginning of the disease. Clinical manifestations range from slight deficits, only demonstrable by means of neuropsychological testing, up to dementia. If a linear involution is supposed for the cognitive worsening in PD, then the relatively subtle cognitive defects should be taken as the earliest signs of dementia implying that PD-MCI concept would be thoroughly equivalent to that used for the early prediction of other dementias among healthy population. Cognitive defects in PD, however, may not follow a normal distribution. While fronto-striatal deficits, such as working memory, set-shifting and free-recall verbal memory appear altered in most patients during long periods of time, certain functions depending on more posterior-cortical regions, such as copying or naming, usually characterize patients with dementia. Fronto-striatal and posterior-cortical cognitive defects may have a different pathophysiological substrates, evolution and prognosis. While fronto-striatal defects appear more related to dopaminergic defects, posterior-cortical defects may obey multiple neurotransmitter failure. Designing criteria to accurately diagnose PD-MCI is highly relevant for clinical treatment, research, care-giving and decision-making. Besides quantitative defects, an operative definition of MCI in PD should clearly distinguish a “risky cognitive profile” among the broad cognitive defects intrinsic to PD. Thus, along with other possible biological markers, from a neuropsychological point of view, posterior-cortical defects probably represent the very syndrome of MCI in PD.
Similar content being viewed by others
References
Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson’s disease. Brain Pathol 20(3):633–639
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8 year prospective study. Arch Neurol 60(3):387–392
Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL (2007a) Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 78(1):36–42
Aarsland D, Kvaloy JT, Andersen K, Larsen JP, Tang MX, Lolk A, Kragh-Sorensen P, Marder K (2007b) The effect of age of onset of PD on risk of dementia. J Neurol 254(1):38–45
Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G (2009) Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72(13):1121–1126
Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M (2010) Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75(12):1062–1069
Aarsland D, Muñiz G, Matthews F (2011) Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord 26(2):334–337
Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70(13):1017–1022
Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH (2007) Defining mild cognitive impairment in Parkinson’s disease. Mov Disord 22(9):1272–1277
Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM (2002) Dopaminergic modulation of high-level cognition in Parkinson’s disease: the role of the prefrontal cortex revealed by PET. Brain 125(Pt 3):584–594
Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW (2007) L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson’s disease. Neuropsychopharmacology 32(1):180–189
Dalrymple-Alford JC, Livingston L, Macaskill MR, Graham C, Melzer TR, Porter RJ, Watts R, Anderson TJ (2011) Characterizing mild cognitive impairment in Parkinson’s disease. Mov Disord
Dubois B (2007) Is PD-MCI a useful concept? Mov Disord 22(9):1215–1216
Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L (2009) Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 24(16):2391–2397
Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707
Foltynie T, Brayne CE, Robbins TW, Barker RA (2004) The cognitive ability of an incident cohort of Parkinson’s patients in the UK: the campaign study. Brain 127(Pt 3):550–560
Galvin JE (2006) Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord 20(4):302–310
Galvin JE, Pollack J, Morris JC (2006) Clinical phenotype of Parkinson disease dementia. Neurology 67(9):1605–1611
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844
Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, Suzuki K, Itoyama Y, Takahashi S, Fukuda H, Mori E (2009) Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov Disord 24(6):854–862
Janvin CC, Larsen JP, Aarsland D, Hugdahl K (2006a) Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord 21(9):1343–1349
Janvin CC, Larsen JP, Salmon DP, Galasko D, Hugdahl K, Aarsland D (2006b) Cognitive profiles of individual patients with Parkinson’s disease and dementia: comparison with dementia with lewy bodies and Alzheimer’s disease. Mov Disord 21(3):337–342
Kulisevsky J (2000) Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson’s disease. Drugs Aging 16(5):365–379
Kulisevsky J, Pagonabarraga J (2009) Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord 24(8):1103–1110
Kulisevsky J, Avila A, Barbanoj M, Antonijoan R, Berthier ML, Gironell A (1996) Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson’s disease patients at different levodopa plasma levels. Brain 119(Pt 6):2121–2132
Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estevez-Gonzalez A (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord 15(4):613–626
Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell A (2008) Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Mov Disord 23(13):1889–1896
Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106(Pt 2):257–270
Llebaria G, Pagonabarraga J, Martinez-Corral M, Garcia-Sanchez C, Pascual-Sedano B, Gironell A, Kulisevsky J (2010) Neuropsychological correlates of mild to severe hallucinations in Parkinson’s disease. Mov Disord 25(16):2785–2791
Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS (2010) Cerebral glucose metabolism of Parkinson’s disease patients with mild cognitive impairment. Eur Neurol 64(2):65–73
Muslimovic D, Post B, Speelman JD, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65(8):1239–1245
Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A (2008) Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord 23(7):998–1005
Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256(3):183–194
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG (1997) Aging, memory, and mild cognitive impairment. Int Psychogeriatr 9(Suppl 1):65–69
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56(3):303–308
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001a) Current concepts in mild cognitive impairment. Arch Neurol 58(12):1985–1992
Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001b) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology. Neurology 56(9):1133–1142
Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2008) Cognitive impairment in 873 patients with idiopathic Parkinson’s disease: results from the german study on epidemiology of parkinson’s disease with dementia (GEPAD). J Neurol 255(2):255–264
Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, Barker RA, Owen AM (2008) Parkinson’s disease and dopaminergic therapy–differential effects on movement, reward and cognition. Brain 131(Pt 8):2094–2105
Setó-Salvià N, Clarimón J, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Combarros O, Mateo JI, Regaña D, Martínez-Corral M, Marquié M, Alcolea D, Suárez-Calvet M, Molina-Porcel L, Dols O, Gómez-Isla T, Blesa R, Lleó A, Kulisevsky J (2011) Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 68(3):359–364
Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology 43(9):1690–1692
Troster AI (2008) Neuropsychological characteristics of dementia with Lewy bodies and Parkinson’s disease with dementia: differentiation, early detection, and implications for “mild cognitive impairment” and biomarkers. Neuropsychol Rev 18(1):103–119
Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130(Pt 7):1787–1798
Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 132(Pt 11):2958–2969
Yeterian EH, Pandya DN (1991a) Corticothalamic connections of the superior temporal sulcus in rhesus monkeys. Exp Brain Res 83(2):268–284
Yeterian EH, Pandya DN (1991b) Prefrontostriatal connections in relation to cortical architectonic organization in rhesus monkeys. J Comp Neurol 312(1):43–67
Acknowledgments
Supported in part by Fundació la Marató de TV3 (060310) and by public research grants from Centro Investigación Biomedica en Red-Enfermedades Neurodegenerativas (CIBERNED)
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Martínez-Horta, S., Kulisevsky, J. Is all cognitive impairment in Parkinson’s disease “mild cognitive impairment”?. J Neural Transm 118, 1185–1190 (2011). https://doi.org/10.1007/s00702-011-0675-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-011-0675-9